Bristol Myers Squibb Co. (0R1F)
London Exchange · UK · prices in USD · close of 20 Oct 2026
Key indicators
| Last close | USD 60.80 |
|---|---|
| 52-week range | 42.04 – 71.07 |
| Return, 1 month / 3 months | −3.6% / −0.2% |
| Return, 1 year / 3 years | +41.6% / +19.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 27.8% |
| Worst drawdown (1 year) | -17.0% |
| Average daily value traded | 1.03M USD |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bristol Myers Squibb is a pharmaceutical company that discovers, develops and markets prescription medicines. Its treatments address cancer, immune disorders, heart and blood vessel conditions, and other serious illnesses. The company serves patients and healthcare providers through hospitals, clinics and pharmacies, and it carries out research and manufacturing across several countries. Bristol Myers Squibb is based in New York City in the United States.
Bristol Myers Squibb Co. trades under the code 0R1F on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bristol Myers Squibb Co. (0R1F) trades on the London Exchange in UK. It last closed at USD 60.80 on 20 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,220 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 41.6% and over the last three months it fell 0.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.8% | ||
| From 52-week high | -10.7% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.2% | ||
| 6-month return | 3.2% | ||
| 12-month return, skipping the last month | 46.8% | ||
| Stability (higher is calmer) | 75 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.0% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.03M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.5% |
|---|---|
| 1 month | −3.6% |
| 3 months | −0.2% |
| 6 months | +3.2% |
| 1 year | +41.6% |
| 3 years | +19.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 63.46 / 59.73 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.31 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Dec 2025 | USD 0.6300 |
| 2 Oct 2025 | USD 0.6200 |
| 2 Jul 2025 | USD 0.6200 |
| 3 Apr 2025 | USD 0.6200 |
| 2 Jan 2025 | USD 0.6200 |
| 3 Oct 2024 | USD 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.